Related Experiment Video

Updated: Apr 27, 2026

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

24.0K

Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma

Zorica Milosevic1, Milica Pesic1, Tijana Stankovic1

  • 1Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Belgrade, Serbia.

Translational Research : the Journal of Laboratory and Clinical Medicine
|July 15, 2014
PubMed

Insights

Anaplastic thyroid carcinoma (ATC) is aggressive. Targeting RAS/MAPK/ERK or PI3K/AKT/mTOR pathways may sensitize resistant thyroid cancer cells to chemotherapy, offering new treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Anaplastic thyroid carcinoma (ATC) is a rare, aggressive, and chemoresistant cancer.
  • Most ATCs exhibit activated RAS/MAPK/ERK and PI3K/AKT/mTOR signaling pathways.
  • Current treatment options for ATC are limited, with a poor prognosis.

Purpose of the Study:

  • To investigate the correlation between RAS/MAPK/ERK and PI3K/AKT/mTOR pathway activity in ATC.
  • To evaluate the potential of inhibiting these pathways to chemosensitize ATC cells.
  • To explore novel genetic-based therapeutic approaches for ATC.

Main Methods:

  • Analysis of phosphatase and tensin homolog, pERK, and pAKT protein expression in ATC patient samples.
  • Mutation analysis of BRAF, RAS, and p53 genes in ATC.
  • In vitro chemosensitization assays using ATC cell lines (FRO and SW1736) with pathway inhibitors.

Main Results:

  • A negative correlation was observed between RAS-MAPK-ERK and PI3K/AKT/mTOR pathway activity in ATC patients.
  • The PI3K-AKT/mTOR pathway was suppressed in patients with NRAS mutations or high pERK expression.
  • In vitro studies indicated that inhibiting either pathway enhanced sensitivity to conventional chemotherapeutics.

Conclusions:

  • Targeting the RAS-MAPK-ERK or PI3K/AKT/mTOR pathways can potentially overcome chemoresistance in ATC.
  • These findings support the development of novel, targeted therapies for anaplastic thyroid carcinoma.
  • Further research into combination therapies targeting these pathways is warranted.

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81